Trial Profile

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 12 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benralizumab (Primary)
Indications Eosinophilic oesophagitis
Focus Registrational; Therapeutic Use
Acronyms MESSINA
Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

21 Oct 2023 This trial has been discontinued in Spain , according to European Clinical Trials Database record.
20 Feb 2023 Status changed from active, no longer recruiting to discontinued.
13 Nov 2022 This trial has been discontinued in Netherlands (Date of the global end of the trial : 25-Oct-2022), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com